Emerging targeted agents in metastatic breast cancer (Q38086421)

28 August 2017

title

Emerging targeted agents in metastatic breast cancer (English)

1 reference

28 August 2017

main subject

metastatic breast cancer

1 reference

Dimitrios Zardavas

1

1 reference

28 August 2017

José Baselga

series ordinal

2

1 reference

28 August 2017

Martine Piccart

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

5 March 2013

1 reference

Nature Reviews Clinical Oncology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

191-210

1 reference

Trastuzumab--mechanism of action and use in clinical practice

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Breast-cancer stem cells-beyond semantics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Intratumor heterogeneity: seeing the wood for the trees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Diverse somatic mutation patterns and pathway alterations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Sequence analysis of mutations and translocations across breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Unravelling the complexity of metastasis - molecular understanding and targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Insulin-like growth factor receptor inhibitors: baby or the bathwater?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The mouse homolog of the hst/k-FGF gene is adjacent to int-2 and is activated by proviral insertion in some virally induced mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Genome-wide association study identifies novel breast cancer susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cyclin D1 in breast cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cyclin E and survival in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A novel interaction between HER2/neu and cyclin E in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Vemurafenib: the first drug approved for BRAF-mutant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

ERK inhibition overcomes acquired resistance to MEK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cancer epigenetics reaches mainstream oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting epigenetic readers in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting MYC dependence in cancer by inhibiting BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting androgen receptor in estrogen receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Shared and separate functions of polo-like kinases and aurora kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cancer stem cells: impact, heterogeneity, and uncertainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

let-7 regulates self renewal and tumorigenicity of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Association of reactive oxygen species levels and radioresistance in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Mammary stem cells and breast cancer--role of Notch signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Aberrant activation of notch signaling in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Wnt/beta-catenin signaling in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Breast cancer stem cells, cytokine networks, and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Gene expression profiling of the tumor microenvironment during breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Stromal gene expression predicts clinical outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The rationale for targeting the LOX family in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

LOXL2-mediated matrix remodeling in metastasis and mammary gland involution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

CXCL12 (SDF-1)/CXCR4 pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Therapeutic targets for bone metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A CXCL1 paracrine network links cancer chemoresistance and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Integrins in cancer: biological implications and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Integrin bi-directional signaling across the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Targeting hypoxia in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Insight into the heterogeneity of breast cancer through next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Harnessing synthetic lethal interactions in anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

21 January 2018

Parallel lives diverge

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The landscape of cancer genes and mutational processes in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Whole-genome analysis informs breast cancer response to aromatase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

The insulin and insulin-like growth factor receptor family in neoplasia: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

TGF-β autocrine pathway and MAPK signaling promote cell invasiveness and in vivo mammary adenocarcinoma tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

What signals operate in the mammary niche?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.29

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

31 March 2020

1 reference

12 December 2020

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

1 reference

12 December 2020

Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis

1 reference

12 December 2020

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer

1 reference

12 December 2020

PARP inhibitors in breast cancer: BRCA and beyond.

1 reference

12 December 2020

Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer

1 reference

12 December 2020

Drug discovery approaches to target Wnt signaling in cancer stem cells

1 reference

12 December 2020

Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer

1 reference

12 December 2020

The hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer

1 reference

12 December 2020

Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma.

1 reference

12 December 2020

Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.

1 reference

12 December 2020

Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue.

1 reference

12 December 2020

10.1038/NRCLINONC.2013.29

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1024347801

0 references

1 reference